Yüklüyor......
Novel agents for advanced pancreatic cancer
Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemothe...
Kaydedildi:
| Yayımlandı: | Oncotarget |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Impact Journals LLC
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4741843/ https://ncbi.nlm.nih.gov/pubmed/26369833 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|